FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
Antoine AdenisThibault MazardJulien FraissePatrick ChalbosBrice PastorLudovic EvesqueFrancois GhiringhelliCaroline MolleviStéphanie DelaineMarc YchouPublished in: BMC cancer (2021)
EudraCT: 2018-003541-42 ; ClinicalTrials.gov: NCT03828799 .